...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychiatric research >Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.
【24h】

Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.

机译：在选择性5-羟色胺再摄取抑制剂无反应和部分反应者中转用度洛西汀：对抑郁的痛苦身体症状有影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Painful physical symptoms (PPS) are common in patients with depression. Our objective was to evaluate the presence of PPS in a sample of SSRI non- or partial-responders with MDD and examine the effect of a switch to duloxetine on those PPS. Outpatients who met criteria for MDD despite having taken an SSRI antidepressant for at least 6 weeks, and who had a Hamilton depression rating scale total score of at least 15 and a clinical global impression of severity score of at least 3, were randomized to switch to duloxetine by either a direct switch or a start-taper switch method. PPS were assessed at baseline and at the study endpoint using various measures including six visual analog scales (VAS) for pain (overall pain, headache, back pain, shoulder pain, interference with daily activities, and time in pain while awake), the pain subscale of the symptom questionnaire-somatic subscale, and the bodily pain subscale of the short form-36 item health survey. Clinically significant levels of pain (mean baseline VAS scores >30 mm) were seen across all VAS pain measures prior to switching. Switch to duloxetine was associated with significant improvements on all pain measures regardless of switch method, and there was evidence for an earlier reduction in pain in the start-taper switch group. In summary, MDD patients who were non- or partial-responders to SSRI treatment were found to have clinically significant pain which improved significantly following switch to duloxetine regardless of the switch method utilized.
机译：抑郁症患者常见疼痛的身体症状（PPS）。我们的目标是评估在MDRI的SSRI无应答或部分应答的样本中PPS的存在，并研究切换至度洛西汀对这些PPS的影响。尽管已服用SSRI抗抑郁药至少6周但仍符合MDD标准的门诊患者，且汉密尔顿抑郁量表的总分至少为15，临床总体印象严重度得分至少为3，才随机转入度洛西汀通过直接切换或开始锥度切换方法。在基线和研究终点使用多种方法评估PPS，包括六种视觉模拟量表（VAS）的疼痛（总体疼痛，头痛，背部疼痛，肩部疼痛，对日常活动的干扰以及清醒时的疼痛时间），疼痛症状问卷-躯体子量表的量表，以及简短的36项健康调查的身体疼痛子量表。切换之前，在所有VAS疼痛度量中均观察到临床上显着水平的疼痛（平均基线VAS评分> 30 mm）。不论采用哪种切换方法，改用度洛西汀均能显着改善所有疼痛，并且有证据表明开始锥度切换组的疼痛较早减轻。总之，发现对SSRI治疗无反应或部分反应的MDD患者具有临床上显着的疼痛，无论采用何种切换方法，在切换至度洛西汀后，疼痛均得到明显改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号